[Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma].
A sandwich radioimmunometric assay using monoclonal antibodies 6G10 and SV2-61 gamma directed to the extracellular domain of the c-erbB-2 oncogene product was developed and the antigen levels in sera from normal donors and patients with breast carcinoma were determined. The antigen levels in normal donors were uniformly low (9.52 +/- 0.91 ng/ml) and 3.0% (2/66 cases) slightly exceeded the cutoff value (11.4 ng/ml). In patients with breast carcinoma, serum c-erbB-2 protein levels increased and the positivity was as high as 45.7% (16/35 cases) in recurrent cases. Determination of c-erbB-2 protein may be a useful marker for serological diagnosis of breast carcinoma.
Clinical Laboratory Division, National Cancer Center Hospital, Tokyo.
F Z
FZ
Yu
K
K
Sugano
H
H
Ohkura
S
S
Mori
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000175:diagnosis*; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay / Q000379:methods; D011518:Proto-Oncogene Proteins / Q000097:blood*; D018719:Erb-b2 Receptor Tyrosine Kinases; D012016:Reference Values
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases